Telix Pharm Ltd (TLPPF) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by and welcome to the TELEX half quarter 2025 results and investor webcast. All participants are in a listen only mode. There will be a presentation followed by a question and answer session. If you would like to ask a question, you will need to press the star key followed by the number one on your telephone keypad. I would now like to hand the conference over to Ms. Kionne Williamson. Please go ahead. Thank you and everybody for joining us this morning and this evening for those joining from overseas. My name is Kyanne Williamson. I'm the SEP of Investor Relations and Corporate Communication at Tealix. You can see there our disclaimer. Just moving forward to slide four, I'd like to introduce today's speakers that are on the line with me. We have Chris Barenbrook, our Group CEO and Managing Director. Darren Smith, our Group Chief Financial Officer. Kevin Richardson, CEO of the Tealix Precision Medicine. and Richard Vallex, CEO of Telex Therapeutics. Today we'll be taking you through the H1 2025 financial results presentation lodged earlier today on the ASX and our operational achievements for the half. This call is scheduled to run for one hour and following the presentation, we'll take questions firstly from analysts on the phone and request that you ask one question at a time and hop back in the queue if you have further questions. If we do not get to your questions on the webcast, we will reply to you directly. Moving on to slide five, please. In today's presentation, our business leaders will be talking to the investments we have made in the business to set it up for long-term value creation. This slide illustrates the scale of our business today, spanning development, commercialization, and global production and manufacturing. It's been a ...